Scarica l'app Stockscreener
1.20
0.84%
0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$1.19
Aprire:
$1.2
Volume 24 ore:
439.34K
Relative Volume:
0.54
Capitalizzazione di mercato:
$37.05M
Reddito:
$680.00K
Utile/perdita netta:
$-75.33M
Rapporto P/E:
-0.1939
EPS:
-6.1898
Flusso di cassa netto:
$-57.38M
1 W Prestazione:
+8.11%
1M Prestazione:
+6.19%
6M Prestazione:
-34.43%
1 anno Prestazione:
-30.64%
Intervallo 1D:
$1.175
$1.23
Intervallo di 1 settimana:
$1.10
$1.27
Portata 52W:
$1.01
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.20 | 37.05M | 680.00K | -75.33M | -57.38M | -6.1898 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Rodman & Renshaw | Buy |
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock - Stock Titan
BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes - Stock Titan
BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares - Stock Titan
BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain - Stock Titan
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioXcel Therapeutics Inc (BTAI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioXcel Therapeutics Inc (BTAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioXcel Therapeutics Inc (BTAI) Institutional Confidence - TradingKey
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
Attention BioXcel Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against BioXcel Therapeutics, Inc. (BTAI) and Encourages Investors to Contact the Firm - TMX Newsfile
What makes BioXcel Therapeutics (BTAI) a new buy stock - MSN
BioXcel Deadline Alert - TMX Newsfile
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel presents data on at-home agitation treatment trial By Investing.com - Investing.com India
BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - marketscreener.com
BioXcel presents data on at-home agitation treatment trial - Investing.com
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - The Manila Times
BioXcel Therapeutics Presents New Data from SERENITY - GlobeNewswire
BioXcel Therapeutics | 424B5: Prospectus - Moomoo
BioXcel Therapeutics Company Profile & Introduction - Moomoo
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria
BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India
BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK
BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com
BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan
BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan
BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan
BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan
BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan
[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus
BioXcel Therapeutics, Inc. (BTAI) reports Q1 loss, lags revenue estimates - MSN
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.23%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):